Byrd JC - Search Results

1

Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.

Cheney CM, Stephens DM, Mo X, Rafiq S, Butchar J, Flynn JM, Jones JA, Maddocks K, O'Reilly A, Ramachandran A, Tridandapani S, Muthusamy N, Byrd JC. Cheney CM, et al. Among authors: byrd jc. MAbs. 2014 May-Jun;6(3):749-55. doi: 10.4161/mabs.28282. Epub 2014 Mar 4. MAbs. 2014. PMID: 24594909 Free PMC article.

2

The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction.

Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D, Reed JC. Byrd JC, et al. Blood. 2002 Feb 1;99(3):1038-43. doi: 10.1182/blood.v99.3.1038. Blood. 2002. PMID: 11807010 Free article. Clinical Trial.

3

Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population.

Perkins JG, Flynn JM, Howard RS, Byrd JC. Perkins JG, et al. Among authors: byrd jc. Cancer. 2002 Apr 1;94(7):2033-9. Cancer. 2002. PMID: 11932906 Free article.

4

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, Vardiman JW, Rai K, Schiffer CA, Larson RA. Byrd JC, et al. Blood. 2003 Jan 1;101(1):6-14. doi: 10.1182/blood-2002-04-1258. Epub 2002 Jul 5. Blood. 2003. PMID: 12393429 Free article. Clinical Trial.

5

Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab.

Byrd JC, Smith L, Hackbarth ML, Flinn IW, Young D, Proffitt JH, Heerema NA. Byrd JC, et al. Cancer Res. 2003 Jan 1;63(1):36-8. Cancer Res. 2003. PMID: 12517774

6

Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.

Bannerji R, Kitada S, Flinn IW, Pearson M, Young D, Reed JC, Byrd JC. Bannerji R, et al. Among authors: byrd jc. J Clin Oncol. 2003 Apr 15;21(8):1466-71. doi: 10.1200/JCO.2003.06.012. J Clin Oncol. 2003. PMID: 12697868

7

Advances in the therapy of chronic lymphocytic leukemia.

Johnson AJ, Mone AP, Abhyankar V, Byrd JC. Johnson AJ, et al. Among authors: byrd jc. Curr Opin Hematol. 2003 Jul;10(4):297-305. doi: 10.1097/00062752-200307000-00008. Curr Opin Hematol. 2003. PMID: 12799536 Review.

8

Rituximab in B-cell chronic lymphocytic leukemia.

Lin TS, Lucas MS, Byrd JC. Lin TS, et al. Among authors: byrd jc. Semin Oncol. 2003 Aug;30(4):483-92. doi: 10.1016/s0093-7754(03)00239-2. Semin Oncol. 2003. PMID: 12939717 Review.

9

Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia.

Farag SS, Flinn IW, Modali R, Lehman TA, Young D, Byrd JC. Farag SS, et al. Among authors: byrd jc. Blood. 2004 Feb 15;103(4):1472-4. doi: 10.1182/blood-2003-07-2548. Epub 2003 Oct 16. Blood. 2004. PMID: 14563637 Free article. Clinical Trial.

10

Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells.

Mone AP, Huang P, Pelicano H, Cheney CM, Green JM, Tso JY, Johnson AJ, Jefferson S, Lin TS, Byrd JC. Mone AP, et al. Among authors: byrd jc. Blood. 2004 Mar 1;103(5):1846-54. doi: 10.1182/blood-2003-08-2836. Epub 2003 Nov 20. Blood. 2004. PMID: 14630799 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

860 results

Search Page

Filters